text:
Spicy Cheesy Kale Chips Even A Monkie Can Love
Contributing Monkie V Ol Blak
Published on September 21, 2011
Filed Under Full Recipe List, Recipes / Desserts, Recipes / Raw, The Ingredient: Cheese Tags Cashew, Cheesy, chips, Kale
Photographer: V Blak (CC)
What do you think, time for a follow up to my Double Down Spicy Cashew Cheese post. I know, I am a one recipe skipping record kind of guy. This time, its Juli Novotny's (kookie karma) famous spicy cheese kale chips. I made them the sameday I made the first patch of cheese, but I never got around to posting the photos or the how to instructions for the kale chips, so today is your lucky day or maybe not.
If you have never had a Kale Chip and think the whole idea of turning a green leafy lettuce into a chip is a bit odd, I am right there with you. The first time I heard about Kale Chips, I thought… what come on. A dried up leaf? But when I got my first bag of Juli's chips, I was sold. WOW… I mean.. they were just great, but maybe they shouldn't be called Chips. They are nothing like a corn or potato chip. They are more like a dried leaf or if you don't fully dry them, they have a texture of a light jerky. Anyways… they are great in their own way. I would eat them any day over potato chips. Especially the cheesy version.
They are more like a dried leaf or if you don't fully dry them, they have a texture of a light jerky
Now lets get into the how to make them part. The batch I made was enough for 8 people at a party or one hungry Monkie. The hungry monkie being me. I didn't share any of them. In fact I ate them all within a day I think. I know… what a piggy monkie. But that is okay, it was my first batch and I earned the right to suck them all down and hey I live alone, so who am I going to share them with anyways? Basil the dog? I don't think Cheese Kale Chips are something that should be on a dogs menu anyways. Carrots, definitely, heavy cashew cheese… hell no.
For this recipe you will need to make the Double Down Spicy Cashew Cheese before you start on the Kale. Follow the link to the recipe. Then follow the instructions below. Plus you will need a dehydrator or a really hot sunny location outside to sun dry thee chips. I am using a dehydrator by Excalibur. Oh and I have added step by step photos to the instructions after the jump, for all you Flesh Monkies out there who are completely new to this thing called Raw Foods. Lets get started… so exciting, right?
For the Cheesy Kale Chips
3 bunches of Organic Kale
1/2 cup of Organic Olive Oil
Celtic Sea Salt or sea salt of your choice
1 patch of Double Down Spicy Cashew Cheese
To begin with, don't be a dirty monkie like me. Wash that kale in the sink or in some spring water. I am famous for just eating anything that comes from the farmers market, straight out of the bag and it never fails, everyone around me says… what a dirty monkie.. wash that stuff. Like a little dirt is going to hurt anyone. Anyways… if your sharing, wash it, trust me, it is not worth the grief you will get. I can still hear those words echoing in my head… "dirty monkie, bad dirty monkie"!
Then in a small bowl, pour in a little olive oil ( about a table spoon ) and a pinch of Celtic Sea Salt. If your looking at the photos above you can see I am a bit heavy with the salt. I use more like a fist of salt.
We are using the oil and salt as the first flavor coating for the chips. The idea is to give it a bit of salty chip flavoring before we move on to the cheese. Also, if you want to skip the cheese part, you could just oil and salt them and call it a day.
To cover the kale in the oil and salt, break the leafs up in to bit size chunks. The size of a large corn chip. Then take each piece and dip it into the oil / salt. Lightly coating it. Then place the newly oiled kale leaf on to the dehydrator tray.
Keep repeating the above steps. You will run out of oil and salt after 6 of so chunks of leaf that you dip in the bowl, so keep repeating the oil / salt steps. Pour in a little more oil and another dash of salt. Continue dipping leaves.
Now that all the leaves are oiled and salted, take your Cashew Cheese and lightly pour it over the leaves on the trays. I also poured some cheese in my hand and scrunched each leaf, making sure the cheese went deep into the leaf. What can I say, I love the cheese and wanted to make sure there was going to be a lot of cheese in each bite. Yes, I washed my hands, I am not that dirty of a monkie. Well, not all of the time.
Now place all your trays in the dehydrator for about 6 to 8 hours at 115 degrees. The timing will vary based on thickness of the cheese and the humidity. The best practice is to just keep checking them and doing a small taste test every few hours the first time you make them. When they are dry enough and taste great… stop the dehydrator and place all the chips in some zip lock bags or a glass storage containers. Or even better, just place them all in a huge bowl and take them out to the dinning room and dig in. I obviously chose the last option.
Remember, if you dry them too long, they will become very brittle and almost burnt like. So don't over dry them and don't turn up the heat too high. I would even say under dry them a little so they still have some flex to them. I like them that way. More jerky like than dried leaf like. The cheese will take longer to dry than the kale.
When they are dry, they should look like the beautiful bowl of Kale Chips below. Look at all those cheey chunks mmmmmm… Okay, I am feeling the itch now, I have to head to the kitchen and make another batch, damn you kale chips! I am so addicted. Chat with you guys later, after my fix! :)


text:
LONDON - After a disappointing loss to Canada Saturday in the semi final of the London 2012 Paralympic Games, the U.S. Paralympic Men's Wheelchair Rugby Team pulled together as one and gained a bit of redemption by defeating Japan in today's bronze medal match.
The U.S. won the game easily, defeating the Japanese 53-43 before a sold out crowd at the Basketball Arena located in Olympic Park.
The U.S. was determined to win today's game and go home with a medal, regardless of the color.
"We had to come out and win a medal today and go home with something, there was no other choice," said Chuck Aoki (Minneapolis, Minn.) who led the team in scoring today with 13 goals.
The U.S. threw its weight around early, coming out aggressive and were able to create several defensive stops. Japan held tough however, and were only down to the Americans by one point, 12-11 after the first quarter.
Play was close throughout the second quarter before the U.S. stopped Japan's Daisuke Ikezaki on the goal line with 1:42 left in the half. After that big stop by the U.S. used that momentum to go on a 3-0 run to close out the half and take a 3 point lead, 24-21, into the third quarter.
In the second half the Americans began to pull away. Powered by a 6-1 run at the end of the third quarter the U.S. was able to extend its lead to eight points, 39-31.
By that point the game was all but done as the Japanese could not stop the Americans potent offensive strikes. The U.S. controlled play in the fourth quarter and pulled away for the victory, 53-43.
This was the American's second win over Japan in these Games after defeating them 64-48 in pool play earlier this week.
Today's win was a total team victory as no one player performed better than another.
Chance Sumner (Colorado Springs, Colo.) was not surprised by the way the team came together to collect this victory.
"It was a team effort because we let it be that way," said Sumner. "We knew we had to man up and come out and represent our country the best way we could."
Although the win is bittersweet for the gold medal favorites, head coach James Gumbert could not have been more proud of his team's play throughout the entire Paralympics.
"I am overwhelmed, they lived our motto today which was 'together as one' and said they were going to leave it all out there for each other," said Gumbert. "As a coach that's all you can ask from your team."
Overall the U.S. finished the Games with a 4-1 record. This is the third straight Paralympic medal for the U.S. in wheelchair rugby.

subset: commoncrawl


text:
First, wow on the Lyric. Installed in my Maccassar/Cedar Taylor and the sound is stunning. I've gone through everysystem out there and this one is IT! My pal who plays through a very complex system with a pendulum was blown away. I run this through a PADI and it's magic.
Two questions-
1)it seems the system has a low shelf frequency. Can you reveal the frequency? If I cut bass on the PADI it seems like nothing happens, which makes me think it has already been cut.
2) is this system ok for nylons? I want to pull the system on my taylor Nylon and am hoping this works just as well in that application.
For the Taylor owners out there, you might want to check out Butch Boswell's tru-plug http://www.butchsguitarrepair.com/Bu...uPlug_USA.html it is a great way to get a clean install on your taylor when you remove the tailblock assembly. Well worth it!!!


text:
HELPFUL HINTS and TIPS for Beading By Machine
|Detail from "Montana Treasure" Art quilt
— I prefer a 90/14 size needle as it works best to pierce all the quilt layers. I also prefer to add my beads once my project is quilted and almost finished, so this size needle works best to pierce all the layers I am working with. Keep in mind that the needle, all the way up to the shaft, must slide through the hole of the bead EASILY. 80/12 needles can work too, depending on the type of thickness and fabric you are beading, as well as the size of the hole of the bead! Note: the finer or smaller the needle, the more easily it can break going through many thicknesses.
|Detail from "Frost on the Zinnias"
--- Do not use a bead taller than 1/4"
--- I recommend using a polyester thread in both top and bottom, matching your background fabric. Polyester as a stronger thread will not be as easily frayed by any roughness that is typical of the inside hole of the bead.
--- be sure to lower your feed dogs!
— Be sure to lower the presser foot BEFORE you start. Remember that you are not using a foot... so it's easy to forget to do this because you can't see the foot physically come down onto your quilt. If you don't lower the presser foot... you will most certainly have a mess of threads on the bottom in no time... not fun!
— "Frame" the needle with your hands, doing your best to keep the the fabric as flat and taut as you can in order to enable the needle to "catch" and make the stitch. At times you will see or hear that it skipped a stitch. This is normal! Keep at it, and be patient! (The large turquoise bead in the center pic below was done by hand)
|Detail from "Montana Treasure"
— If desired, you may hoop the area to be beaded (I recommend a screw-type hoop with a narrow width that will fit underneath the foot of a machine) But for me, this means that the tightness of the hoop is likely to warp my quilt, so I don't do this in most instances.
— If you use a hoop, corral your beads in the hoop
— Tie off (the same way you tie off for free-motion quilting)
— May use a stiletto or tweezers to move/push the beads for placement
|Detail of Beading on Angel Quilt: "Psalm 91:11 for Jamie"
— For exact placement of a bead, use the hand-heel, guiding the needle tip until it just grabs the hole of the bead, and gently drag the bead to where you want to stitch it. Then, using your hand-wheel, sink the needle into the center of the bead. Then bring the needle back up and take a stitch on the same side of the bead as when you first went in with your needle. For example, if you stitched from the left side of the bead, then go out on the left side, and the bead will turn onto it's "side." VIP: make 3-5 tiny stitches between each bead, which ensures that if one bead breaks off, all the beads won't! Tie off at the end, stitching 5-8 times.
Keep at it!
As always, some things never change... practice, practice... PRACTICE...!
You will enjoy the extra special detail of dimension and sparkle that is worth this extra special effort!


text:
The Men's Guard T-Shirt showcases Cotton / Polyester construction, for luxurious comfort and moisture wicking performance. Engineered for lifeguards, the Guard T-Shirt is a perfect choice for the pool or beach, offering protection from the sun and accelerated dry time to combat the heat. Featuring an oversized Guard Logo for increased visibility, the TMGF3 separates you from the crowd and authenticates your role. Safety's first, but style and performance matters.
TYR Fabrication: 60% Cotton / 40% Polyester
TYR Fabrication: 60% Cotton / 40% Polyester
Size Chart
No reviews submited yet
Product Questions & Answers (0)
No questions asked yet
Women's Guard Element Shirt


text:
Moving may bring about many "To-Do" lists along with a new set of tasks that you may not expect. But none of these hassles should outweigh the joy of starting a new chapter in a new home. Polka Dot Design has created a foolproof way to let friends and family know of your new address with our beautifully designed collection of moving announcements. Browse our selection and check a few things off your list today.
We carry a wide array of moving cards to make notifying loved ones of your new abode a simple and painless process. There is no reason to let certain tasks overshadow the bliss that is moving into a new home. Selecting the right card is an easy one--simply choose the design that fits you best, customize the style, color, text, and font to your liking, and voila! Your moving announcements are ready to be shipped. Straightforward and effortless.


text:
IBM: Creating a Demand Acceleration System
April 22, 2010
Eric Andrews, VP, demand programs, strategy & management systems, IBM, discussed IBM's new demand acceleration system.
Members Only Content
This content is available to ANA Members only. Please login below or create an account.
You may already be a member. Find out if your company is already an ANA member.


text:
Paris, France / Munich, Germany July 1, 2016In pursuit of continuing high quality service delivery, ARTTIC has completed its takeover of GABO:mi.
The GABO:mi people, who are joining us, strengthen ARTTICs position as European market leader said Christian Baumhauer, the President of ARTTIC. Our combined excellent knowledge and experience will provide us with the means to expand services, deliver deeper support for more proposals and projects. This is great news for our clients and our people. This will allow ARTTIC to further sharpen its strategic focus on providing mission-critical services."
GABO:mi is a German company with a strong track record of successful projects in biological sciences. In addition to the strengthening of ARTTICs leadership in consultancy and management services for European research and technology-related partnerships, this take-over also reinforce ARTTIC resources in Germany, especially in the Horizon 2020 fields for health, demographic change and wellbeing.
As part of the takeover, responsibility for supporting 30 projects and 20 employees will be transferred to ARTTIC. In addition, ARTTIC is acquiring :milliarium, a web-based project management tool developed and used by GABO:mi for the management of European projects, especially H2020 and Innovative Medicines Initiative (IMI).
About GABO:mi
Founded in 2005, GABO:mi gained extensive expertise with diverse EU funding instruments and managed more than 45 medium- and large-scale collaborative projects in FP7, Horizon 2020 and IMI.
GABO:mi was ranked on place 3 among the TOP SMEs in the Final FP7 Monitoring Report in March 2015, being the best German enterprise in this list. Additionally, GABO:mi was certified according to DIN EN ISO 9001 obliging for excellence according to the European Foundation for Quality Management (EFQM).
As ARTTIC, the GABO:mi employees have widespread experience in the management of European projects. The project managers are familiar with the structures of research institutions and with their governing principles. With their expertise and overview they are a perfect partner to shoulder all management and dissemination tasks a successful European project requires.
About ARTTIC
ARTTIC assists clients from all business and research sectors, small and large, private and public, to ensure the success of their collaborative research & innovation ventures. During close to 30 years of success, ARTTIC developed and demonstrated expertise in the set-up and management of more than 300 large-scale ambitious projects of which 44 already successful under H2020 first calls, Clean Sky calls included. Based on its long-standing experience in a range of funding programmes across scientific and technological domains, ARTTIC helps clients to move from strategic plans to effective competitive research and development of innovative solutions, resulting in successful applications and high-performance businesses.
Founded in Paris in 1987, ARTTIC is now a group of companies with main offices in France (Paris and Toulouse), Germany (Munich and Berlin), Belgium (Brussels), England (Derby) and Israel (Tel Aviv). In 2015, ARTTIC has been ranked first SME in Europe by the European Commission considering the number of grant agreements signed by ARTTIC.
The entire GABO:mi team is very pleased of the start of our new projects, which we have successfully applied for with our partners at the EC:
Stroke and dementia rank among the most pressing health issues in Europe. Cerebral small vessel diseases (Small Vessel Diseases, kurz: SVDs) account for more than 30% of strokes and at least 40% of dementia cases. The new research project SVDs@target, coordinated by Prof Dr Martin Dichgans at the Ludwigs-Maximilians-University in Munich will focus on exactly these SVDs and try to elucidate the mechanisms underlying SVDs to develop new therapeutic interventions. SVDs@target is funded with 6m Euro by the EC under the Horizon2020 programme and started on 1 January 2016.
Mental, cognitive, vision and hearing health issues in elderly people are amongst the top 10 public health challenges in Europe. They frequently occur co-concurrently and have an additive negative effect on quality of life and mental well-being. Therefore, the European funded project SENSE-Cog will promote earlier detection of sensory, cognitive and mental impairments to enable swift interventions and prevent deterioration. Coordinated by Dr Iracema Leroi and Dr Piers Dawes, both at the University at Manchester, SENSE-Cog started on 1 January 2016 and is funded with 6m Euro by the ECs H2020 programme.http://www.sense-cog.eu/
From January 2016 onwards the FOLSMART consortium, consisting of eight partners from four European countries, will continue working on further improvement of treatment possibilities for rheumatoid arthritis (RA). FOLSMART is coordinated by Prof Artur Cavaco-Paulo from the Associacao Universidade empresa para desenvolvimento TecMinho (Portugal). During the predecessor project NANOFOL, the group has successfully developed the therapeutic strategy of the novel treatment method and within the next four years the consortium aims for clinical validation of the therapeutic approach. The start-up FOLMATECH will be established as part of the project and will eventually produce the product and take care of its IP rights and commercialisation.http://www.folsmart.eu
On 1 November 2015, the new H2020 project RELENT has started. RELENT is coordinated by Prof. Dr. Renate Kain from the Medical University in Vienna. The project goal is to develop better therapies for chronic autoimmune diseases, such as rheumatoid arthritis and vasculitis. The consortium aims to identify common mechanisms responsible for the persistence and outcomes in these diseases that cause considerable mortality and morbidity. The results should be rapidly translatable into clinical practice for the benefit of patients. RELENT combines the resources of seven leading European research institutions and two from the US and Australia. Three SMEs will supply specific reagents and translate the results to biomarker development. GABO:mi is looking forward to accompany the consortium for the next four and a half years.http://www.relent.eu/
The European Commission has funded a new research project in haemophilia A under its Horizon 2020 programme and GABO:mi is one out of six partners. The main objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell based therapy to treat the bleeding disease, haemophilia A (caused by genetic deficiency in clotting factor VIII (FVIII)). The innovative concept of HemAcure consists of the GMP conform isolation, FVIII gene correction and expansion of autologous endothelial cells, which are then transplanted into a proprietary prevascularized GMP manufactured medical device designed for therapeutic cells. The transplanted cells release FVIII into the bloodstream of the patient over an extended period of time, significantly improving the quality of life and reducing the side effects of the disease.
The project, which started on 1 November 2015, will run over three years and is led by Dr. Joris Braspenning of the University Hospital Wuerzburg, Germany.
Diamond should help to produce fuels and chemicals from carbon dioxide and light. This is the goal of a new research consortium receiving around 3.9 million Euro in funding from the European Union. Project start of DIACAT was 1 July 2015. The innovative project is coordinated by Anke Krueger at the University of Würzburg, GABO: mi is responsible for the entire project management.http://www.diacat.eu/
GABO:mi is partner of a new European Research Project which aims at avoiding complications after stroke.
Stroke is the worlds second largest cause of death and the second cause of long-term disability. Elderly patients have a high risk of complications after stroke, such as infections or fever. These complications are strongly associated with a higher risk of death or dependency. The PRECIOUS project will assess whether a pharmacological strategy to prevent the most common complications in elderly patients with acute stroke reduces the risk of death or long-term disability. The project started on 1 June 2015 and runs till June 2020.
Top News! GABO:mi on rank 3 of the TOP 25 SMEs
On rank 3 (rank 4 last year) GABO:mi is the best enterprise in Germany belonging to TOP 25 SMEs (Small and Medium Enterprises) in Europe. This information is part of the latest and final FP7 Monitoring Report of the European Commission, published in March 2015.
A strong consortium of 32 EFPIA, academic and SME-partners will collaborate in this project of a duration of 5 years.
The goal of this project is to identify and also treat tumors on the basis of blood-based biomarkers. The focus is on the improvement of available technologies, as well as medication and other treatments, all in all for the well-being of the patient.http://www.cancer-id.eu
1 January 2015 is the day: the project TREGeneration, coordinated by Prof. João Mascarenhas Forjaz Lacerda at the Instituto de Medicina Molecular in Lisbon starts.
TREGeneration has a project duration of 5 years, comprises 8 participants in Portugal, Germany, Belgium, Italy and Great Britain, and is funded with 6 million Euro.
In five parallel clinical trials the effectiveness of donor regulatory T-cells for patients with graft-versus-host disease after hematopoietic stem cell transplantation will be examined.http://www.tregeneration.eu
In a bibliometric analysis of ongoing IMI projects EU-AIMS was rated as the best IMI project on various performance measures.
On scientific output:
1) EU-AIMS has the highest citation impact to date of all IMI projects and 4 times the world average impact.
2) EU-AIMS has the highest percentage of highly cited papers (42% of EU-AIMS publications are in the top decile of publications for journal category and year of publication).
For more specific details: Bibliometric Report
For more Information on the Project: www.eu-aims.eu
GABO:mi is Project Management Partner of the EU-funded FP7 project DEM-CHILD. The project dealing with research on better diagnose methods and finding ways to slow down NCL disease (batten disease) causing childhood dementia. The project lasted three years and ended in September 2014. For further information on NCL see the video Laura Story including explanations of Prof. Jon Cooper (KCL), who was partner in DEM-CHILD.
EPITARGET, a new FP7 Health project, started on 1 November 2013. The consortium is led by the University of Lund with Prof. Merab Kokaia as coordinator and includes members from Sweden, Germany, France, Finland, Italy, United Kingdom, Poland, the Netherlands and Israel. The work will be funded by the EC with nearly 12 million Euros in the course of the next five years.
Epilepsy is a devastating condition affecting over 50 million people worldwide. Current antiepileptic drugs provide only symptomatic relief but cannot cure the condition. This is why EPITARGET is focused on identifying novel biomarkers for epileptogenesis to be able to explore new ways of how to treat epilepsy.
On 1 October 2013, the European Research Project EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) was launched! It is coordinated by Prof. Markus Zabel, University Medicine Göttingen, and it will be funded by the EC with almost 6 million Euros. For the next four years, researchers and physicians of 19 participating institutes located in Europe will analyze the effectiveness of prophylactic implantation of cadioverter defibrillators (ICDs) in Europe.
GABO:mi has supported EU-CERT-ICD during the proposal stage and will be the project management partner for the whole duration of the project.more
The project includes a non-randomised, non-invasive, advanced diagnostics, observational trial in candidates and patients for primary prophylactic ICD therapy. Moreover, a large European registry will be generated collecting available data on prophylactic ICD treatment for comparative analysis. Data from both, the prospective study and the registry will be compared with results from a meta-analysis of existing literature data to estimate QoL-adjusted cost-effectiveness from actual cost comparisons and Markov decision models with attention to sub-groups, regional, and sex comparisons.EU-CERT-ICD is expected to provide important novel information to validate or challenge current guideline indications for primary prophylactic ICD treatment.
On 1 October 2013 the project PRONIA coordinated by Dr. Nikolaos Koutsouleris (Ludwig-Maximilians-Universität München) started its work. The European Commission funds the project with an amount of 6 million Euros.
The project goal is to implement reliable and accessible prognostic tools facilitating the prediction and prevention of psychoses. This objective will be reached by generating a prognostic system based on use routine brain imaging and complementary data.
The long-term aim is also to commercially exploit these prognostic services through internet-based telemedicine applications. This will provide psychosis risk profiling tools to diverse target groups in the healthcare markets, including care-givers, the pharmaceutical industry and research institutions.
The consortium consists of research institutions, SME and industry partners: University of Munich, University of Basel, University of Birmingham, University of Turku, University of Udine, University of Melbourne, as well as Dynamic Evolution, General Electric Global Research and General Electric Healthcare.
GABO:mi supported PRONIA already during the proposal stage and is looking forward to accompanying the consortium throughout the next five years.
CFMATTERS, a new FP7 Health project, started on 1 October 2013. The consortium is led by University College Cork with Dr. Barry Plant as coordinator and includes members from Ireland, the United Kingdom, France, Germany, Belgium and the United States of America. The work will be funded by the EC with nearly 6 million Euros in the course of the next three years.
CFMATTERS is focused on the development and trial of personalized antibiotic treatment for patients with CF during respiratory infections. The treatments will be adapted to the bacteria that cause the infection using next generation DNA-sequencing methods. By implementing a personalized approach for antibiotic prescriptions, ultimately the development of antimicrobial resistances can be limited.http://www.cfmatters.eu
On 1 October 2013 the international European research project CENTER-TBI has started. The project is coordinated by the University of Antwerp, Prof. Andrew Maas, and co-coordinated by the University of Cambridge, Prof. David Menon. The consortium consists of 38 international partners and will run for 6,5 years. The European Commission funds the project with an amount of 30 million Euros.
CENTER-TBI aims to advance the care for patients with traumatic brain injury (TBI), a field in medicine with one of the greatest unmet needs. The research aims to 1) better characterise TBI as a disease, and describe it in a European context and 2) identify the most effective clinical interventions for managing TBI.
FemNAT-CD a new FP7-Health project started on 1 September 2013. Apart from the Goethe University Frankfurt am Main with Prof. Christine Freitag as coordinator, the network includes 16 research institutions and companies from eight EU-states established in Aachen, Amsterdam, Southampton, Basel, Heidelberg, Birmingham, Dublin, Regensburg, Terassa, Bilbao, Szeged, Athens, Munich, Ulm, and Trier. The EU is going to fund the work of the researchers with nearly 6 million Euros over the coming four years.
FemNAT-CD is a multi-center study which deals with paediatric conduct disorders characterized by aggressive traits and/or social impairment with an operating range reaching from preclinical research to treatment.
The key aims of the FemNAT-CD consortium are to identify biomarkers and to study disease mechanisms from pre- to postpubertal female CD (conduct disorder) as well as new psychological and pharmacological treatment options for female adolescent CD targeting emotion processing abilities.
GABO:mi has been already successfully supporting Professor Freitag in the application phase und will accompany the project throughout the whole project duration with professional project management.
On 1 September 2013 the international European research project CULPRIT-SHOCK was started. The project is coordinated by Prof. Dr. Holger Thiele (University of Luebeck, Germany). The European Commission funds CULPRIT-SHOCK for 4 years, with an amount of nearly 6 million Euros.
The CULPRIT-SHOCK study hypothesis is to explore if culprit vessel only PCI with potentially subsequent staged revascularization in comparison to immediate multivessel revascularization by PCI in patients with cardiogenic shock complicating acute myocardial infarction reduces the incidence of 30-day mortality and/or severe renal failure requiring renal replacement therapy.
On 1 September 2013, the project EpimiRNA, coordinated by Prof. David Henshall (Royal College of Surgeons in Ireland) and Prof. Felix Rosenow (Universität Marburg), started its work. The consortium consists of 16 partners from 8 European countries, the USA and Brazil.
Through highly collaborative, inter-disciplinary and inter-sectorial research, EpimiRNA will explain the mechanism by which miRNAs contribute to epileptogenesis, characterize genetic variation of miRNA in patients, evaluate seizure-suppressing effects of miRNAs in experimental models, identify novel miRNA modulatory molecules as potential future therapeutics, and develop miRNAs as prognostic markers to identify patients who respond to novel, non-pharmacological therapeutic interventions including brain stimulation. EpimiRNA will generate the necessary critical mass in biomedical, clinical and industry/SME research to track, treat and prevent seizures and improve the clinical management of epilepsy patients.
GABO:mi supported EpimiRNA during the proposal stage and is looking forward to accompanying the consortium throughout the whole project duration (five years).
On 1 August 2013, the project HypOrth, coordinated by Prof. Christoph H. Lohmann (University of Magdeburg), started its work. The project aims to develop hypoallergenic material for endoprotheses, pursuing two major goals: HypOrth intends to improve the understanding and diagnosis of complications associated with an implant, primarily focussing on adverse immune reaction and infection. Based on these insights the project will develop innovative approaches for renewals in orthopaedic arthroplasty with improved biocompatibility.
The collaboration between research institutions, industry and SME partners is essential for this project. The consortium consists of research institutions based in Germany (University of Magdeburg), Estonia (University of Tartu), Poland (Instytut Obróbki Plastycznej, Metal Forming Institute, Poznan), Hungary (Hungarian Academy of Sciences, Budapest) and Denmark (Danish Technological Institute Centre for Chemistry and Biotechnology, Aarhus), as well as of SME and industry partners from Spain (Progenika, Derio Vizcaya ) and Switzerland (Mathys AG, Bettlach).
GABO:mi is looking forward to accompanying the consortium throughout the whole project duration (five years).
On 1 May 2013, the new FP7-Health project T-Control started. Funded for three years with nearly 6 Mio Euros by the EC, the five project partners Universitätsklinikum Würzburg, Anthony Nolan Trust London, Academisch Ziekenhuis Leiden, Stage cell therapeutics GmbH Goettingen, GABO:mi Munich will develop two new Streptamer-based GMP (good manufacturing practice) compliant cell selection processes and their corresponding cell products. The products are a multivirus and a tumor specific CD8+ T cell product (multispecific T cell product), which shall diminish adverse reactions in cell therapies.http://www.t-control.info
In the last HEALTH-Call of the 7th Framework Programme, we were again very successful! The contract negotiations are almost finalized. The scientific coordination of the projects goes to 7 German, 2 Irish,1 Belgian and 1 Swedish institutions:
- Ludwig-Maximilians-University Munich, DE
- University Hospital Wuerzburg, DE
- Johann-Wolfgang-Goethe-University Frankfurt a. M., DE
- Heinrich-Heine-University Duesseldorf, DE
- University Medical Center Goettingen Georg-August-University Goettingen, DE
- University of Luebeck, DE
- Otto-von-Guericke-University Magdeburg, DE
- University College Cork, Ireland
- Royal College of Surgeons, Ireland
- University Hospital Antwerp, Belgium
- University of Lund, Sweden
Together with our consortium partners, we are looking forward to the Kick-Off-Meetings of these very exciting research projects, in autumn 2013!
HydroZONES - our new research project in the programme nanotechnologies (NMP) - started on the 1 January 2013. Apart from the University Hospital of Würzburg with Prof. Jürgen Groll as coordinator, the network includes research institutions and companies from Heidelberg, Dresden, Aachen, Munich, Oxford, Utrecht, Groningen, Pamplona and the Portuguese city of Leiria. Even an Australian team is involved. The EU is going to fund the work of the researchers with 9.75 million Euros over the coming five years. Healing cartilage defects: This is the objective of the international research network HydroZONES: Bioactivated hierarchical hydrogels as zonal implants for articular cartilage regeneration. Implants that are structured like natural tissue are to provide durable repair of defects in the joint.
GABO:mi has been already successfully supporting Professor Groll in the application phase und will accompany the project throughout the whole project duration with professional project management.
Press release
GABO:mi manages its 4th IMI JU project: The European Lead Factory, the largest pan-European drug discovery platform. The 5-year project is coordinated by Bayer HealthCare (Germany). Its funding volume amounts to 196 million Euros. In this project an unprecedented collaboration between industry and academia should pave the way to easily translate findings into treatments for patients and should be the foundation for growth in drug development in Europe.http://www.europeanleadfactory.com
On 1 December 2012 SysmedIBD (Systems medicine of chronic Inflammatory Bowel Disease), a 5-year-project with 12 million Euros EC funding, started its work. Coordinated by Prof. Werner Müller (University of Manchester) the consortium of 12 academic and SME partners focuses on innovative research approaches to chronic inflammatory bowel diseases. http://www.sysmedibd.eu
An international consortium of scientists coordinated by Prof. Graham Thornicroft of the Institute of Psychiatry of Kings College London has launched the EMERALD global mental health project to improve mental health systems in low- and middle-income countries. The objectives of the EMERALD Project are to establish an adequate, fair and sustainable resourcing, integrated provision of physical and mental health and improved coverage of care. EMERALD brings together collaborators from Ethiopia, India, Nepal, Nigeria, South Africa and Uganda.
The project startet on 1 November 2012 and is funded by FP7 for the coming 5 years. GABO:mi has supported Emerald from the proposal stage on and will support and manage the research of the international during the project period.
On rank 4 (rank 14 last year) GABO:mi is the best enterprise in Germany belonging to TOP 25 SMEs (Small and Medium Enterprises) in Europe. This information is part of the latest FP7 Monitoring Report of the European Commission, published in August 2012.
Coordinated by Dr. Birgit Köhler, Charité Berlin, the project DSD-Life started on 1 October 2012. The project is funded by FP7 with a lifecycle of 4 years. The project consortium consists of experienced and well-known scientists in the areas of endocrinology, psychology and ethics. Uniting 16 international project partners the project aims for sustainable improvement of clinical and medical care for patients with disorder in sex development (DSD) on European level. http://www.dsd-life.eu
Coordinated by Prof. Franz Schaefer from the Universitätsklinikum Heidelberg, Germany, this FP7 funded 5-year project started its work on 1 October 2012.
EURenOmics unites 19 academic and 8 SME partners from 10 European countries and the US in an international consortium of scientific excellence, bringing together leading clinical, genetic and translational researcher in an unprecedented clinical research network in the field of rare kidney disease.
As the highest ranking proposal of its call, the project was awarded 12 million Euros to study the underlying causes and molecular pathways of several rare and neglected kidney disorders with eminent need and potential for diagnostic and therapeutic progress, using latest Omics technologies. Besides the elucidation of fundamental scientific questions, the project will focus strongly on the development of innovative diagnostic tools and biomarkers as well as models for the screening of potential therapeutic agents. This could open the possibility of individualized therapies for the benefit of the more than 30,000 newly diagnosed patients per year suffering from these debilitating kidney diseases. GABO:mi is proud to be a partner in this project and has supported EURenOmics from the proposal stage. http://www.eurenomics.eu
The aim of this ambitious project is to develop a highly-powered and efficient software engine (SENATOR) capable of individually screening the clinical status and pharmacological and non-pharmacological therapy of older people with multimorbidity in order to define optimal drug therapy, highlight ADR risk, indicate best value drug brand for selection and provide advice on appropriate non-pharmacological therapy. 9 Partners under the coordination of Dr. Denis O`Mahony, geriatrician from the University College Cork, Ireland committed themselves for the next 5 years to run the project which started on 1 October 2012 and received 6 million Euros from the European Commission. GABO:mi has supported the consortium starting with the grant application stage and will be responsible for the project management.http://www.senator-project.eu
Coordinated by Prof. Dr. Günter Neumann at the University of Hohenheim (near Stuttgart), the project BIOFECTOR started on 1 September 2012. Having succeeded in a tough competition, BIOFECTOR is funded with 6 million Euros by the European Commission. This project consists of 22 European partners of which 9 partners are small and medium enterprises, actively contributing to the research objective: Improving knowledge on plants and bio-effector interactions with their related physiological and chemical mechanisms. GABO:mi supported BIOFECTOR during proposal stage and is the project management partner during this project of a duration of 5 years.http://www.biofector.info
On 1 July 2012 the international European research project Re-Liver (Bottom-up reconstitution of a biomimetic bioartificial liver) was started, coordinated by Dr. Joris Braspenning (Medicyte GmbH). The long term goal of this European project is to utilize bioartificial liver organoids as alternative to solid organ transplantation. GABO:mi supported the consortium, consisting of five European partners, already in the proposal phase and will take care of the project management during the three-year project duration.
This research project is receiving funding of 4.2 million Euros from the European Commission.
On 1 April 2012, the IMI (Innovative Medicine Initiative) project EU-AIMS started. EU-AIMS is the largest single grant for autism research in the world and the largest for the study of any mental health disorder in Europe which will be led by Dr. Will Spooren (Roche) and Prof. Declan Murphy (Kings College London). EU-AIMS brings together top scientists from 24 academic European institutions and Biotech companies with a wide range of expertise, and partners them with major global drug companies from the European Federation of Pharmaceutical Industry Associations (EFPIA) including Roche, Eli Lilly, Servier, Janssen Pharmaceutica, Pfizer and Vifor Pharma; as well as world leading autism charities including Autism Speaks (USA). The project will study new methods for the development of drugs for autism spectrum disorder (ASD). The research of EU-AIMS will be funded by the IMI, the EFPIA companies and from Autism Speaks over the duration of five years with 29.6 million Euros. http://www.eu-aims.eu
In the last Calls of FP7, we were again very successful. Currently, we are in contract negotiations with 7 projects. Among these, 4 coordinating institutions are located in Germany:
- Universität Hohenheim, D
- Medicyte GmbH (SME) Heidelberg, D
- Universitätsklinikum Heidelberg, D
- Charité Berlin, D
- University of Manchester, UK
- University College Cork, IR
- Kings College London, IoP, UK
This impressive result is best proof and evidence for a winning team. We are proud of actively supporting the European spirit of research together with our research partners!
On 1 February 2012, the European research project EuroHYP-1 started. The project is a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke and is coordinated by Prof. Stefan Schwab at the Universitätsklinikum Erlangen, Germany. The project includes 35 European partners and one international partner organization from Australia. It will be funded by the European Commission over the duration of five years with 10.9 million Euros. GABO:mi has successfully supported EuroHYP-1 from the proposal phase on.
Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so its social and economic burden will grow with the ageing of the European population. Systematic review of experimental studies suggests that hypothermia is the most promising intervention identified to date. Therapeutic cooling is effective in reducing ischaemic brain injury following cardiac arrest, and hypothermia is therefore considered by experts the most promising treatment for patients with acute ischaemic stroke, next to reperfusion strategies.
The EuroHYP-1 trial is a pan-European, open, randomised, phase III clinical trial which will assess the benefit or harm of therapeutic cooling in 1500 awake adult patients with acute ischaemic stroke. The investigators involved in the EuroHYP-1 consortium are leading European experts in statistical design and analysis, therapeutic hypothermia, imaging, health economics, ultrasound, biomarkers, and trial execution (implementation and monitoring); furthermore, the consortium involves European patient and family advocacy groups and small and medium-size enterprises, in order to ensure the successful enrolment of patients and the data analysis.
On 1 January 2012 the European research project DORIAN (Developmental Origins of healthy and unhealthy Ageing: the role of maternal obesity) was started, coordinated by the Institute of Clinical Physiology-CNR, Consiglio Nazionale delle Ricerche in Pisa, Italy. Dr. Patricia Iozzo and her team were successfully supported by GABO:mi from the proposal stage onwards. The European Commission funds DORIAN for 3 years, with an amount of 3 million Euros.
This multidisciplinary project will generate a better understanding of the basic mechanisms of early life development and ageing, which may translate into the improvement of health and quality of life during the entire life course. In particular, the Consortium of DORIAN will investigate and analyze the impacts of maternal obesity on the way of ageing and its associated degenerative pathologies in the offspring through the duration of life.http://www.dorian-fp7.eu
On 1 January 2012 the European research project EUROFORGEN-NoE (European Forensic Genetics Network of Excellence) started. The project is led and coordinated by the University of Cologne/Institute of Legal Medicine, Prof. Peter Schneider. Its consortium consists of 12 European partners and involves outstanding and well-known scientists within the field of forensic genetics, aiming for the initiation of a sustainable Network of Excellence. GABO:mi supported the consortium successfully during the proposal phase. The project will run for 5 years and is funded by the European Commission with an amount of 6.6 million Euros.http://www.euroforgen.eu
On 1 January 2012 the international European research project NILVAD (A European multicentre double-blind placebo-controlled phase III trial of nilvadipine in mild to moderate Alzheimers disease) started, coordinated by the Trinity College Dublin (TCD), Ireland. Prof. Brian Lawlor and his team were already successfully supported by GABO:mi during the proposal stage. The European Commission funds NILVAD for 5 years, with an amount of 6 million Euros. more
Alzheimers disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than 440,000 million each year (www.alz.org, 2010).
There is therefore an imperative to develop new treatments for AD that have disease modifying effects. NILVAD performs a double-blind placebo controlled study that will test the efficacy and safety of nilvadipine in 500 subjects with mild to moderate AD over a treatment period of 18 months. Male and female patients with mild to moderate AD aged between 50 and 90 with a range of medical morbidities and frailty will be included in the study. If this trial is successful, nilvadipine would represent an advance in the treatment of AD patients and would have a major impact on the health and social care costs incurred in Europe by this neurodegenerative disorder.
On 1 January 2012 the international European research project DITAC (Disaster Training Curriculum) started, coordinated by the Universitaetsklinikum Bonn. Dr. Philipp Fischer and his team were already successfully supported by GABO:mi during the proposal stage. The European Commission funds DITAC for 3 years, with an amount of 4 million Euros.more
A European multi-disciplinary team of experts is collaborating to develop a standardised curriculum for international crises management hereby referred to as DITAC. The DITAC project aims to develop a holistic and highly structured curriculum for first responders and strategic crisis managers that are tasked in dealing with disasters on a national and international scale. The curriculum will tackle dynamic challenges facing disaster incident managers in order to enhance the efficiency, efficacy, coordination, coherence and appropriateness of their response efforts. These skills are crucial because of an alarming increase in the frequency, intensity and complexity of disasters while governments are simultaneously facing budgetary constraints on humanitarian aid due to overwhelming sovereign debt. less
The European research project WAKE-UP (Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial) started on 1 December 2011. The project is coordinated by the University Medical Center Hamburg-Eppendorf, Prof. Christian Gerloff. GABO:mi already supported the consortium successfully during the proposal phase. The consortium consist of 13 European partners and will run for 5 years. The European Commission funds the project with an amount of 12 million Euros.more
The objective of the research proposed in the WAKE-UP project is to provide expanded treatment options for acute stroke improving the outcome of stroke patients, thus reducing the burden of stroke. For this purpose, WAKE-UP will conduct an investigator-initiated multicentre randomised double-blind placebo-controlled trial designed to test efficacy and safety of magnetic resonance imaging (MRI)-based intravenous thrombolysis in patients waking up with stroke symptoms or patients with unknown symptom onset.http://www.wakeup-stroke.eu
On 1 November 2011, the European research project EpiPGX (Epilepsy Pharmacogenomics: delivering biomarkers for clinical use) started, coordinated by the University College London. Professor Sanjay Sisodiya and his team were already successfully supported by GABO:mi during the proposal stage. The European Commission funds EpiPGX for 4 years, with an amount of 6 million Euros.more
The purpose of EpiPGX is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs). The project will use genome-wide analyses, including next-generation sequencing, in large, well-phenotyped patient cohorts to identify genome-based biomarkers, to improve use of current antiepileptic drugs (AEDs) and identify new therapy targets. SMEs, which are central to this project, will be able to take the data forward for development of clinical tests.http://www.epipgx.eu
On 1 October 2011, the research project DEM-CHILD (A Treatment-Oriented Research Project of NCL Disorders as a Major Cause of Dementia in Childhood) started. The consortium is led by Dr Angela Schulz, University-Clinic Hamburg-Eppendorf and consists of 10 international partners. The outstanding aspect of this project is the collaboration with a partner in India where dementia in childhood is as critical an issue as in Europe. GABO:mi supported the consortium successfully during the proposal phase, and is now an active partner taking care of all project management tasks. The project duration is 3 years and the funding by the European Commission amounts to 3 million Euros. http://www.dem-child.eu
The FP7 project EuroSkinGraft started on 1 October 2011 and is coordinated by the University Zurich. The project deals with a novel generation of skin substitutes to clinically treat broad spectrum of severe skin defects. GABO:mi is the project management partner, who has successfully accompanied the consortium through the proposal phase. The consortium consists of 7 European partners and is funded for 5 years with an amount of 6 million Euros by the European Commission.
Report on skin grafting on Swiss TV TV broadcast
Together with some researchers of the project CARDIORISK, we managed to win a grant for a follow-up project. The project ProCardio deals with cardiovascular Risk from Exposure to Low-dose and Low-dose-rate Ionizing Radiation. ProCardio is coordinated by Prof. Michael J. Atkinson, Helmholtz Zentrum for Environmental Health Munich. The project is due to start on 1 October 2011. For a period of three years, we support the researchers in project management and the development of a website.http://www.procardio.eu
GABO:mi belongs to TOP 20 SMEs
On position 14 GABO:mi is the only enterprise in Germany belonging to TOP 20 SMEs (Small and Medium Enterprises) in Europe. This information is part of the latest FP7 Monitoring Report of the European Commission, published in August 2011.
In the last Calls of FP7, we were very successful. Currently, we are in contract negotiations with 11 projects. Among these, 6 coordinating institutions are located in Germany:
- Universitätsklinikum Hamburg-Eppendorf, D (two projects)
- Klinikum der Universität zu Köln, D
- Universitätsklinikum Bonn, D
- Helmholtz Zentrum München, D
- Universitätsklinikum Erlangen, D
- University College London, UK
- Kings College London, IoP, UK
- Trinity College Dublin, IR
- Universität Zürich, CH
- Consiglio Nazionale delle Ricerche, Pisa, I
This impressive result is best proof and evidence for a winning team. In twofold dimension: on the one hand, a successful team together with the researchers and on the other hand, a committed project management team. We are proud of actively supporting the European Idea and spirit of research!
Four of these eleven projects have already carried out successful PR work:
- Trinity College Dublin: "Clinical Trials for New Alzheimer's Disease Treatment to be Awarded European Commission 6 million Funding"
press release
press release Alzheimer Research Forum
- Universität Zürich: Report on skin grafting (Project EuroSkinGraft) on Swiss TV TV broadcast
- Universitätsklinikum Hamburg-Eppendorf: Report on stroke (Project Wake-up) on German TV TV broadcast
- Universitätsklinikum Erlangen: Report on hypothermia (Project EuroHyp) on German TV TV broadcast
PREDI-NU Continuation of a success story
Together with the researchers of the project EAAD (European Alliance Against Depression), we managed to win a grant for a follow-up project. The project PREDI-NU (Preventing Depression and Improving Awareness through Networking in the EU) deals with the improvement of education and the prevention of depressions. The main objective is the development of an Internet-based self-management platform for young people with mild depressions. The project is due to start on 1 September 2011. For a period of three years, we support the researchers in project management, development of a website and an IT-platform.
On 1 January 2011, our second IMI JU project (Innovative Medicines Initiative) OncoTrack, led by Dr David Henderson, Bayer Schering Pharma AG and Prof. Hans Lehrach, Max-Planck Institute for Molecular Genetics started. Over the next five years, in total 18 renowned universities, biotech companies and European pharmaceutical companies join forces for the research of biomarkers in the field of cancers, in order to better adjust therapies for the patient.
Coordinated by Dr. Sascha Sauer of the Max-Planck-Institute for Molecular Genetics, ESGI (European Sequencing and Genotyping Infrastructure) will develop a European infrastructure for DNA sequencing and genotyping. ESGI will provide access to top-notch DNA-sequencing establishments, with a total budget of 10 million Euros.
Over the last 30 years, there was massive progress in the field of biomedical research. At the same time, costs dropped dramatically. The quality of sequencing methods was increased. In the meantime, genomes can be examined entirely and molecular networks can be analysed efficiently. ESGI will support Europe in becoming the leading region in genetic research. For more information: www.esgi-infrastructure.eu
In the course of the next 5 years, ENS@T-CANCER (European Network for the Study of Adrenal Tumours – Structuring clinical research on adrenal cancers in adults) takes care of research on adrenal gland cancer. This type of cancer is a rare cancer with very poor prognosis. The diagnosis usually happens that late, that tumour cells have already started settling on neighbouring organs. The European Commission funds this project with an amount of 6 million Euros.more
In the next 5 years, the ENS@T-CANCER consortium will develop new methods for the diagnosis and treatment of adrenal cancer. At the same time, a network of treatment centres is to be established via ENS@T-CANCER, in order to provide the most current and modern methods to the patients. It is the international cooperation that enables the research on such types of rare cancer.
The scientific coordinator of this project is Prof. Felix Beuschlein, of the Ludwigs-Maximilian-Universität (LMU) in Munich. Besides GABO:mi as project management partner, there are another 13 partners in this project.
On 1 November 2010, the international European research project INTRICATE (Infection triggers of chronic autoimmunity) started, coordinated by the Medical University Vienna. Prof Dr Kain and her team were already successfully supported by GABO:mi through the proposal phase. The European Commission funds INTRICATE for four years, with an amount of 6 million Euros.more
INTRICATE is a unique project which brings together renowned scientists from various academic institutions and SME's, of whole Europe and the USA. The project should find out the links between infections and autoimmune diseases. INTRICATE examines the connection between specific infections and the autoimmune disease "Systemic Vasculitis", which is characterized by an inflammatory destruction of the blood cells, arteries and veins. The results of INTRICATE should then be translated into clinical applications. That way, it will be possible to make predictions and to carry out monitoring of the inflammatory processes which trigger Systemic Vasculitis.http://www.intricate.eu
The FP7 project The HIP Trial" started on 1 October 2010 and is coordinated by the University College Cork in Ireland. GABO:mi is the project management partner, who has successfully accompanied the consortium through the proposal phase. The consortium consists of 13 European and Canadian partners and is funded for 5 years with an amount of 5,7 million Euros by the European Commission.more
HIP (Management of Hypotension In the Preterm Extremely Low Gestational Age Newborn) is a clinical trial, in which better therapies for preterm births are developed. According to conservative studies, about half of all preterm births suffer from too low blood pressure. This condition often leads to brain damage, disturbance of the neuronal development with a livelong disability as a consequence and is further associated with an increased mortality. It is the aim of the study to develop efficient medicines, which do not only increase the babies' chances of survival, but also protects them from long-term disabilities. less
Copyright © by GABO:mi mbH & Co. KG, e-mail: dialog(at)gabo-mi.com


text:
College Success Workshops
Motivation and Goal Setting Workshop
Tue Jan 29, 2013
3:00 pm - 4:00 pm
The Learning Center offers free, drop-in workshops that cover a wide variety of topics that support student achievement.
This is a one hour workshop to assist students with understanding motivation and setting academic goals.
A list of all workshops can be found at the Learning Center Event Calendar.
CSM College Center Building 10, Room 220, Learning Center1700 West Hillsdale Blvd.
San Mateo, CA 94402 USA
Browse Events at this Location
Event Contact InfoRon Andrade
(650) 574-6571
Share this EventEmail to a Friend
Save to Your CalendariCalendarvCalendar
Google Calendar
Yahoo! Calendar
Windows Live Calendar


text:
"Physio & Massage Very good"
Was this review helpful?
You must have a professional account to set your favourite review. Click here to upgrade now!
© 2017 WhatClinic.com | Privacy Policy | Terms of Service
Global Medical Treatment Ltd trading as WhatClinic.com 12 Duke Lane Upper, Dublin 2, Ireland
firstname.lastname@example.com, Tel: +353 1 652 0520: Co. Reg. No. 428122 All Rights Reserved


text:
Horoscopes for your children
August 26, 2005
Bob Huber: Local Columnist
Don't fret over those expensive items you bought for your kid as he entered school this fall. You should instead smack your forehead and cry, "I shudda bought a Student Horoscope!"
Allow me to explain.
The 2005 Old Newsman's Horoscope is hot off the presses, and it's just what your kid needs. After thousands of hours of mind-boggling research straight from the backsides of cereal boxes and certain in-depth periodicals found in grocery checkout lines, we have perfected zodiac predictions for kids.
So let me proceed with a sample reading of your student's stars, guaranteed to show that Cancer the Crab was here long before Willie the Whale:
CAPRICORN THE GOAT (For students born between Dec. 23 and Jan 19): If you were born under this sign, you should invest in some good psychotherapy for your parents. Frankly, as a goat, it's your odor that drives them nuts. Cast off your promiscuous Capra image too, and stop eating the trays and utensils in the cafeteria.
AQUARIUS THE WATER CARRIER (Jan. 20-Feb. 29): You should be careful in 2005. If you insist on packing around so much stuff in your backpack, you could get in big trouble, herniawise. As a final thought, just remember that anyone can lead a horse to water, but if you can't teach it to do algebra, what good is it?
PISCES THE FISH (Feb. 20-March 21): If your school is near water, keep a wary eye out for teachers who tie flies. Worms are bad medicine too. What you want is more music classes where they teach that old ballad, "Boop, boop, didum, downum, wanum, chew, and they swam and they swam all over the dam." That'll brighten your school year.
ARIES THE RAM (March 22-April 20): Unless you're a girl, it's OK to be a ram. The same holds true for Taurus the Bull. But if you're a girl, that's embarrassing. Talk about your classic sexual bias. Someone should have labeled some zodiac signs "Winnie the Ewe," and "Elmira the Heifer."
TAURUS THE BULL (April 21-May 21): School will get worse in 2005. My advice is: Work hard to master another year's math, but shy away from the basics like how many lawyers it takes to kick a dog. Show some authority. Teachers will fight you, but what do they know? If they're so smart, how come they're still in school?
GEMINI THE TWINS (May 21-June 22): Better start rat holing money right now, because you'll spend twice as much as you did last year. That holds true every year until you finish college. Just remember that old Boy Scout motto, "Be prepared, even if it means stealing your mother's butter and egg money to buy a pretty girl a Coke."
CANCER THE CRAB (June 23-July 23): You've probably figured out by now that no one likes you very much, but that's because your classmates are jealous, especially if you're a blond. If you're a boy, you've got many other important things to worry about, like what greasy stuff to use on your hair. Get a life.
LEO THE LION (July 24-Aug. 23): Many times this year you'll wake up in the middle of history class longing for catnip. Lions are cats, you know. You'll also get the screaming twitches when your mother makes you wear that new shirt she bought you, the one with little pink bunnies on it. That's because you're not as young as you used to be, but you're not as old as you're going to be either.
VIRGO THE VIRGIN (Aug. 24-Sept. 23): Just the mention of your zodiac sign makes other kids snicker, but don't fret. If you're a boy, you might stop wearing dresses this year. If you're a girl, keep your halo on tight, no matter what your classmates say. You're both ugly anyway.
LIBRA THE SCALES (Sept. 24-Oct. 23): In 2005, you shouldn't spend so much time at the cosmetic counter sniffing body lotion. Concentrate instead on new clothes. Have your parents go to the bank and take out a second mortgage or sell your big sister.
SCORPIO THE SCORPION (Oct. 24-Nov. 22): Get a new pair of cowboy boots this school year and get rid of those awful, smelly sneakers. Then get some jeans and dump those baggy, low-hanging carpenter's pants. Then watch your back.
SAGITTARIUS THE ARCHER (Nov. 23-Dec. 22): The sign for Sagittarians used to be called "The Bowman," but that was determined to be sexist by certain women's groups, which is a problem you'll face this year. The world is a lot more complicated than it was when your parents were little, so be gentle with them.
Bob Huber is a retired journalist living in Portales. He can be contacted at 356-3674.


text:
David Akers (1975/88): The 1907 High Relief with the Flat Rim is not especially rare, but it is considerably more rare than the Wire Rim variety, at least two to three times as rare, in fact. Because of the beauty of the design and the fact that it represented the first significant design change in the 58 year history of the Double Eagle series, High Reliefs were saved in quantity and preserved with great care. As a result, many Flat Rim High Reliefs exist and a substantial portion of them are in choice or gem uncirculated condition. This issue is high priced but not rare; its history, beauty and low mintage have made it one of the most popular U.S. gold coins and this popularity, rather than any inherent rarity, has brought about the High Relief's comparatively high price.
Some Wire Rim coins, especially circulated ones, have much, if not most, of their wire rim missing and so it is sometimes difficult to tell whether a particular coin is a Wire Rim or a Flat Rim merely by looking at the rim. However, since the varieties resulted from the use of collars, they are also distinguishable by looking at the lettered edge. On the Flat Rim variety there is a number of raised lines on the edge running parallel to the rim. These are absent on the Wire Rim variety.
All High Reliefs were struck a minimum of three to five times , so it is not surprising that they are always fully struck. Most specimens are very frosty but many of them have a very satiny texture and often display a myriad of raised die swirls and scratches in the fields. Lustre is always excellent and the color is most often a light to medium greenish gold. A few specimens have a coppery hue, however.
Phillip H. Morse Collection of Saint-Gaudens Coinage - Heritage 10/2005:6527, $264,500 - Heritage 1/2007:3796, $316,250


text:
Tyler Walker Wins Mono SkierX Gold
ASPEN, Colo. - Right from the beginning, it was clear the Mono Skier X title was going to be Tyler Walker's (Franconia, N.H.).
The New Hampshire native took the lead out of the gates and as his other competitors struggled, Walker pulled away to claim the gold.
Not bad for a guy who just arrived in Aspen this morning after claiming first place in both downhill races at the International Paralympic Committee World Cup in Sestriere, Italy.
"I got the silver last year, so this just feels awesome," a jet-leged but victorious Walker said. "I was in Italy yesterday, and now I am on the snow here in X Games. It was a great course this year; I have to give it up to X Games in Aspen."
Aspen native Sam Ferguson, who fell at the start of the race, took silver in front of the hometown fans with last year's gold medalist Kees-Jan van der Klooster grabbing the bronze.
"After I wrecked at the beginning, I just kept thinking I have to stay in this thing," Ferguson said. "And it paid off. It feels awesome to win this in front of my home crowd. I can't thank Aspen enough for the commitment to this sport."
Mono Skier X is a fast and furious course race that features disabled mono skiers racing over tabletop jumps, banked turns, rollers and gaps. Like the other X course disciplines at Winter X, Mono Skier X is a fusion of motorcross and downhill racing on snow.


text:
A collection of stories from individuals with disabilities, families, friends, and disability service providers in Tennessee
Showing stories 1 - 3 of 3
Results related to: 6 to 13 years / Health Care / Parent
"I don't want to burden Joshua, but at the same time I want him to know he is a part of his success story.
"There should be strict laws for the day care centers to protect my child from being turned down because he has a disability."
"When Joey was first diagnosed with autism, I came across an article that said children with autism oftentimes grow up with very few friends. That hurt. I look to his school as a place where he can be with others. When he is out of school, I hope we will
find new places where he can be with his peers."


text:
Cats can sometimes be mysterious creatures that aren't always as open about their emotions as other animals. Because of this, many of their actions may be difficult to interpret. According to VCA Animal Hospitals, one strange behavior some cats exhibit occurs during petting. The feline may seem to initially enjoy the petting, but will suddenly bite or paw aggressively at the person doing the rubbing.
VCA reports that this is commonly known as the "go away" bite, or what happens after the cat no longer wants to be petted. For some cats, being interactive with their owners doesn't merit being petted. Certain cats simply want to sit on their owners lap without being touched. If a cat is enjoying being petted for some time, owners tend to miss the subtle signs that their cat has had enough.
According to VCA, signs like a slight posture change, tail twitching, body tensing, dilated pupils or ear movements are cues that it's time to stop petting. More obvious signs include hissing or growling.
However, if a cat had previously loved being petted, but now shies away from it or lashes out suddenly, this may signal that the cat is experiencing medical problems. Whether it be a skin condition, anxiety or something more serious, if a cat is acting differently, it should be brought to a veterinarian health clinic.


text:
CONTEST: Bucky Acronym Game (#BAG)
- March 31, 2011
It's contest time again… but this time you don't need a set to win a free set.
People have always asked us where the name "Buckyballs" comes from.
We know the answer, but that doesn't mean we can't have a little fun. Lets assume BUCKY stood for something… it'd have to be crazy… and fun (just like Buckyballs)… but what would it be?
Post your best Bucky Acronym to our Facebook or on Twitter and you'll automatically be entered to win a free set of Buckyballs.
On Facebook
Post your Bucky Acronym like this…
… to our Facebook page before 11:59PM EST Sunday, April 3rd.
Ideally, you'll post it as a comment right on the contest announcement – but we won't fault you if you forget that bit and just post it to our wall.
Either way, we'll pick our two favorite on Monday and award them a free set of Buckyballs!
On Twitter
It's going to work just the same way, only you've got to add the hash-tag #BAG and short link http://bit.ly/hWKxTO to this page. Like this…
Banged Up Cats Kinda Yell http://bit.ly/hWKxTO #BAG
… before 11:59PM EST Sunday, April 3rd. We'll pick our two favorite and award them a free set of Buckyballs Monday!
The fine print: There's not much. Must be 18 to enter. Winners are chosen by Team Buckyballs. Have fun. That is all.
- TAGS: Bucky ball game, buckyball game, Buckyballs game, Contest, Free Buckyballs, win Buckyballs
- Leave a comment


text:
The Center for Learning Resources offers services such as workshops and tutoring. The CLR posesses textbooks for students to use while they are in the CLR. Students may use the textbooks even if they are not meeting with a tutor, but the textbooks must remain within the CLR premises. Ask the receptionist if you are looking for a particular textbook and do not see it on the bookshelves.
You must be an active student, faculty, or staff member at UNH to utilize the services offered by the CLR. As we are primarily a tuition-funded program, we do not offer tutoring to other parties at this time.


text:
Why Book With Us
- No booking fees
- Flexible cancellation policies
- 24 hour customer service
- Like booking hotel direct
- Privacy
- Security
Email Offers
Singapore Hotels > Amara Sanctuary Resort Sentosa > Location
Amara Sanctuary Resort Sentosa
Amara Sanctuary Sentosa is an award-winning 121-room corporate resort hotel/a rich tapestry of styles/ blending Lush Nature/ Colonial Heritage/ and Chic Contemporary/ to create an idyllic retreat close to Singapore best beaches/retail mall/ and the city Financial District. Located just less than 3 minutes away from the Harbourfront offices and deluxe Vivo City retail mall/ the Central Business and Financial District is only ten minutes away. These ultra conveniences and discreet location make the resort hotel the select choice for discerning business and leisure guests. Amara Sanctuary provides free wired broadband internet in room/ free car parking for in house guest/ free entry to Sentosa upon presenting of confirmation letter at the gantry/ free shutter service to and from Harbourfront and free gym access. Extra bed is not available for 20-31 Dec 2013.
1 Larkhill Road Sentosa Island
Singapore, 099394 SG
Check In Time: 14:00:00
Check Out Time: 10:00:00


text:
BEIJING(AP) Teddy Riner has taken a liking to Beijing, where people have started calling him ``The Great Wall.''
The French media are building him up as their country's greatest athlete since football's Zinedine Zidane. He's on just about everybody's short list of athletes most likely to go home with a gold. And he's only 19.
``I can't say I have waited for this day,'' Riner said Wednesday. ``I don't feel like I have waited at all.''
Riner's ascent to the top of judo has been as stunning as his physique. He stands 204 centimeters tall and weighs 129 kilograms (6-foot-8, 285 pounds), towering over most of his opponents.
Pushed into the sport at age six by his parents, who were worried that he needed to find a focus for his energies, the Guadeloupe-born, Paris-raised Riner in 2006 won the European and world titles, then the next year did it again - at 18 - on the senior level, becoming the youngest man to win the world heavyweight judo championship.
He did it in style, too, beating two former world champions along the way. When he fights next Friday, he said, look for more of the same.
``Everything is perfect,'' he said. ``The food, the atmosphere. I am completely ready.''
So are the French fans.
A decade ago, men's judo was all about a rivalry between French double Olympic gold medalist David Douillet and Japanese world champion Shinichi Shinohara. Douillet, one of France's most respected sports figures, beat Shinohara on points in a close match for the Sydney gold in 2000, and also won a controversial decision over him at the world championship final in 1997 in Paris.
Both athletes have retired. But the rivalry hasn't died.
Many Japanese have never forgotten Shinohara's disappointments, and are hoping for a touch of revenge from Satoshi Ishii, Japan's national champion. The French, meanwhile, simply have been looking to regain the premier Olympic judo gold.
Overall, Japan is always the team to beat.
The Japanese have 31 golds in judo to 10 for France, which is its closest rival. The Japanese have never failed to win at least one gold since judo became an official sport in Tokyo in 1964. They won a record eight golds in Athens.
But Douillet, who is in Beijing to watch the competition, said Riner has given Japan cause to worry.
``When I quit the sport, they thought that they could win everything, that they would dominate everything,'' he told The Associated Press. ``Now, they have reason to be concerned. France has returned.''
Riner said he is taking no chances. He is skipping the games' opening ceremony, and will be spending most of the next week training or quietly watching DVDs.
``I don't want to waste my energy standing around for three hours,'' he said of the opening ceremony, which will be held Friday. ``I am in my own bubble, and I need to stay there.''
He boasted, however, that he is ``happy to take on anyone.''
Ishii, who is known as something of a brawler, is a classic Japanese judo star, with shaved head, cauliflower ears and a thick, low-to-the-ground build. He also knows a little something about being a prodigy - he was Japan's youngest national champion when he won two years ago, also at 19.
But Ishii has never won Olympic gold, and is largely unproven in major international meets.
He erupted into tears after winning his berth by taking the national title in April, vowing to uphold his country's honor by winning in Beijing.
``The outcome is everything,'' he said.


text:
Here's how RW members rated this race (191 votes).
In short: I have run a better races and I have ones a whole lot worse.In full: I had not heard much in the way of complements about this race before I ran it, but I thought why not give it ago and see what it's like.It could do with a few more toilets, but then again so could every race I have every run. If you want a PB this is the course for you.Its not the most scenic but if your after that PB who cares.You had a slight delayed start due to the kids race but thats not the end of the world.Overall I think they have done a fairly decent job. And there a good chance I will be back next year. Date of review: March 13, 2011
In short: Fast course and well organised eventIn full: A good promotion by Nice Work - this is the third of their events I've run. This is a good course for a fast time and although few would say it's scenic it's virtually car free and an easy route to follow. Seeing the finish line infatable from a mile away spurs you on to! Date of review: March 13, 2011
In short: Much improved from last two yearsIn full: Do the people of Lydd want this race and do any of them even know it is happening? Organisation, marshals, water stations etc were far better than 2009 and 2010 when I did my last two races here. The downside was that there was virtually no support at all apart from friends and relatives at the start and finish. Out on the course I think I must have counted about a dozen (and I am being generous) spectators including one small boy standing at his front gate cheering everybody on.As I understand it ftom previous years some of the proceeds of this race go to the local Mayor's charity appeal. Well, to be blunt, the people of Lydd really need to get off their derrieres and give this race more support. This has the potential to be a good race, it is fast, flat and perfect PB material, The organisation is getting there. The car park exit conflicting with runners still finishing was a bit of a pain and could have been reduced by giving a cut-off time and telling folk that they could not get out of the car park until at least two hours after the race started, by that time the spread out runners could have been accommodated alongside cars going out.All told far better, I got a PB by 5 minutes, so I am happy and will be back.Date of review: March 13, 2011
In short: Fast, flat raceIn full: Enjoyed this one - nice to have the rural route although the flatness of some parts meant you could see way in to the distance with points that seem ages to reach.Start had the main facilities needed - could have done with a couple more loos to cut down the time waiting but otherwise all OK. Delayed start for some reason - may be better to start the main race then have the junior race get underway once the start line cleared?Felt sorry for the worms! What was going on - it was a deathtrap for so many!! Must have been the shock of the vibrations from all of the runners on quiet lanes!Course marking was accurate (measured against garmin) until mile 6 but then went out a bit - finished in 12.98m. Otherwise a potential PB course although the lap around the field first and the potholes on the track took a bit of navigating.Drivers should have been more respectful for finishers - some of those who left early didn't seem to care about the fact they were getting in the way of runners.Thanks for a good race though - will certainly be back for this one again.Date of review: March 13, 2011
In short: Nice flat courseIn full: ...wait for the moaners but personally I think this race went very well considering the trouble they seem to have with local people not supporting there race. Very flat course and well done to the organisers ( think before you have a whinge about how hard it must be to organise and set up one of these races especially after people let you down at the last minute ).Date of review: March 13, 2011
In short: Worms on the road...In full: There is a miserable cheap feel about the event. Poor consideration given to how people are to park, and where to route the runners, so at the end of the race there was a dangerous mix of tired runners attempting to use the same pot-holed track as impatient drivers trying to get out and go home.The marshals were largely indifferent, some were grumpy, and a blessed handful were supportive.The start was delayed. There wasn't any tannoy system that I could hear. There were few facilities. It was people standing in a damp field unsure what was happening.If the money was going to a charity I wouldn't mind, but privately organised events such as these need to be better. People have paid for a decently organised event. It's not the same as a local club putting on an event, or a charity putting on an event. There are different attitudes toward a purely commercial operation.Negatives aside, I enjoyed the course. Being flat it meant I did a PB of 2.15.10 - my previous fastest half was Henley back in Oct 2006 when I did 2.19.47. The scenery was pleasant - it was all peaceful rural, with lambs and swans and daffodils just emerging. The weather on the day was better than expected. A little chilly to start, then settled down into a steel-grey March morning. The dreaded wind was little more than a breeze - and mostly wasn't noticed; there was a bit late on during the return, but it didn't hamper running and it wasn't cold.There's a decent pub, The Dolphin, for drinks afterwards, with free nibbles on the bar. A chap gave me a standing ovation as I left because he could see my medal. I was pleased with that.Date of review: March 13, 2011
In short: Had to be done as on our doorstep :)In full: First time that I have taken part. the route was part of our trainng runs....funny seeing so many other runners. enjoyed it and got a PB. Thanks to all the Marshals and the scouts who manned the water stations. Lynn Date of review: March 13, 2011
Date of review: March 28, 2010
In short: Water Farce In full: I've supported this race every year since it came back, but as the race has grown in status the organisers have failed to keep pace and this was evident on Sunday.Toilet facilities in the hall were inadequate with the queue out of the building into the carpark.1st water station had one girl on it who was still setting up as runners were arriving,she tried her best but simply could not cope and was soon overwhelmed.2nd station,When I got there we were told there was a limit of one cup only as we were told they were down to their last 5 litres (I got there in sub 1.40 pace so don't know how slower people behind coped) and runners were even asking the St.Johns Ambulance for water !3rd station almost 1.5 miles further on from where it should have been. I (and several other runners)made a point of tracking down the Race Director at the finish and and pointing out these issues.We all know that drinks stations are a basic necessity and that dehydration can have significant effects both mentally and physically and whether they like it or not Race Organisers have a duty of care to look after the health and welfare of runners who participate in their events.The upshot was the R.D disputed that there were any problems with lack or drinks station staff or water shortages and was totally dismissive of these issues and disinterested in our concerns.(despite the fact that we were are all experienced club runners not novices)I note that "Nice-work" have other events planned for later in the year including a trip to the Himalayas (which until Sunday I was considering doing) but after this fiasco I would not feel confident about their ability to deliver or to look after the welfare of runners in their care.I would respectfully suggest that they need to get the basics sorted before trying to be more ambitious. The reputation of this race and it's organiser)is as far as I am concerned is in tatters and at present I would not recommend this race to anyone.Date of review: March 18, 2010
In short: Great 1st ever raceIn full: This is the 1st race i ever ran,and rather enjoyed it!!!Mile marakers were clear,marshalls were great!!the 2 young kids were brilliant handing out water!!It Would have been nice for someone to have a loudspeaker at the beginning to start the race,and also a much clearer finishing line!looking forward to next time!Date of review: March 18, 2010
Visit the official Runner's World page
Follow Runner's World on Twitter
Click here
Other Natmag-Rodale Sites
Run For Charity
Injury Clinics
About Runner's World